BIOMX INC (PHGE) Stock Price, Forecast & Analysis
USA - NYSEARCA:PHGE - US09090D3017 - Common Stock
PHGE Key Statistics, Chart & Performance
The current stock price of PHGE is 0.39 USD. In the past month the price decreased by -37.07%. In the past year, price decreased by -49.46%.
PHGE Latest News, Press Relases and Analysis
PHGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About PHGE
Company Profile
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Company Info
BIOMX INC
22 Einstein St., Floor 4
Ness Ziona MARYLAND 7414002 IL
CEO: Jonathan Solomon
Employees: 55
Phone: 972723942377
BIOMX INC / PHGE FAQ
What does PHGE do?
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
What is the current price of PHGE stock?
The current stock price of PHGE is 0.39 USD. The price decreased by -5.8% in the last trading session.
What is the dividend status of BIOMX INC?
PHGE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHGE stock?
PHGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting PHGE stock to perform?
8 analysts have analysed PHGE and the average price target is 15.81 USD. This implies a price increase of 3953.85% is expected in the next year compared to the current price of 0.39.
Can you provide the market cap for BIOMX INC?
BIOMX INC (PHGE) has a market capitalization of 10.35M USD. This makes PHGE a Nano Cap stock.
PHGE Technical Analysis
PHGE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHGE. While PHGE seems to be doing ok healthwise, there are quite some concerns on its profitability.
PHGE Financial Highlights
Over the last trailing twelve months PHGE reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS decreased by -60.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.8% | ||
| ROE | -96.91% | ||
| Debt/Equity | 0 |
PHGE Forecast & Estimates
8 analysts have analysed PHGE and the average price target is 15.81 USD. This implies a price increase of 3953.85% is expected in the next year compared to the current price of 0.39.